-
Shionogi, Nagasaki University, Saraya and Connect Afya Enter into a Comprehensive Partnership Agreement to Support Antimicrobial Stewardship in Kenya
-
ESCMID Global 2025: Shionogi Presents Real-World Data Demonstrating Better Clinical Outcomes When Fetcroja® / Fetroja® (Cefiderocol) Is Used as Empiric or Documented Therapy as Compared To Salvage Therapy for the Treatment of Gram-Negative Bacterial Infections
-
Exclusive Licensing Agreement with Link Healthcare, a Clinigen Company for Cefiderocol in Australia and New Zealand
-
Conclusion of a Comprehensive Collaboration Agreement with Osaka Metropolitan University in the Field of Infectious Diseases — Aiming to Establish the ‘Osaka Model’ for a City Resilient to Infectious Diseases through Industry-Government-Academia Collaboration
-
Approval for “Fetroja®”(cefiderocol) in South Korea
-
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats
-
Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Qpex’s Partnership to Advance its Portfolio of Antibiotics Addressing Drug-Resistant Infections
-
Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.
-
Qpex Biopharma Announces Presentations on Phase 1 and Nonclinical Data on Three Clinical Stage Oral and IV Products Targeting Antibiotic-Resistant Bacterial Infections at 2022 ID Week Meeting
-
Qpex Biopharma Announces Presentation of Clinical Data for Ultra-Broad Spectrum β-lactamase Inhibitor Xeruborbactam and the Lipopeptide QPX9003 at ECCMID 2022 Meeting